Pratik Shah, CEO of Auspex Pharmaceuticals, bought 8,333 shares of Auxpex Pharmaceuticals (Stock Symbol: Enter ASPX) at $12 per share for a total amount of $100 thousand on February 10th, 2014.
Auxpex Pharmaceuticals is based in San Diego, CA.
On Feb. 10, 2014, Auspex Pharmaceuticals, Inc. (ASPX), a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced the completion of its initial public offering of 8,050,000 shares of its common stock at an initial public offering price of $12.00 per share.
According to Capital IQ, Auspex Pharmaceuticals has a market cap of $596 million, an enterprise value of $539 million, and non-existent trailing 12 month revenues.
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing novel medicines for the treatment of orphan diseases. The companys product candidates are used to address medical needs primarily in hyperkinetic movement disorders, such as chorea associated with Huntingtons disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications. Its lead product candidate includes SD-809 that is in Phase 3 registration clinical trial for the treatment of chorea associated with Huntingtons disease. The companys other product candidates under development comprise SD-254, deuterium-containing analog of venlafaxine, which has completed two Phase 1 clinical trial; SD-560, a deuterium-containing analog of pirfenidone that is in the preclinical stage of development; SD-970, a deuterium-containing analog of ticagrelor, which is in the preclinical stage of development; SD-900, a deuterium-containing analog of tofacitinib that is in the preclinical stage of development; and a deuterium-containing analog of ketamine.
Pratik Shah’s most recent annual compensation from Auspex Pharmaceuticals is a salary of $592,500, $9,606 in other compensation, and a total compensation of $1,085,240. Mr. Shah is 44 years old.
According to his biography, Dr. Pratik Shah is President, Chief Executive Officer, Director of Auspex Pharmaceuticals, Inc. He has served as our President and Chief Executive Officer since October 2013 and as a member of our board of directors since June 2007. Dr. Shah served as Chairman of our board of directors from September 2008 to October 2013. Dr. Shah has been a partner in the venture capital firm Thomas, McNerney & Partners since 2004. Prior to joining Thomas, McNerney & Partners, he co-founded Kalypsys, Inc., a private clinical-stage pharmaceutical company, where he served as the Chief Business Officer from 2001 to 2004 and was responsible for the overall strategy, business development and operations of the company. Before co-founding Kalypsys, Inc., Dr. Shah was at McKinsey & Company, a consulting firm, from 1999 to 2001 where he focused on biotechnology and venture capital projects. Prior to McKinsey & Company, Dr. Shah co-founded NephRx Corporation, a start-up company focused on the discovery of therapeutic proteins for renal disease, where he served as the Vice President of Operations from 1997 to 1999. In addition to serving on our board of directors, Dr. Shah currently serves on the board of directors of Ocera Therapeutics, Inc., a publicly-traded clinical-stage biopharmaceutical company, and the following private company board of directors: Cebix Incorporated and SGB, Inc. He holds a B.S. in Biological Sciences from the University of California, Irvine and both a Ph.D. in Biochemistry & Molecular Biology and an M.B.A. in Finance from the University of Chicago. We believe that Dr. Shah’s experience in managing, financing and consulting with biotechnology companies and having played a key role in founding and building several life sciences companies qualifies him to serve on our board of directors.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.